Barrow, Hanley, Mewhinney & Strauss’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
Other funds holding HAE
RRAM
Barrow, Hanley, Mewhinney & Strauss's HAE Position: Q1 2026 in Review
Barrow, Hanley, Mewhinney & Strauss sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 523,113 shares — an estimated $41.9M sold.
Barrow, Hanley, Mewhinney & Strauss first reported a position in HAE in Q4 2013 and held it in 16 quarters. The position peaked at $105M in Q1 2015. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Barrow, Hanley, Mewhinney & Strauss reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
- Barrow, Hanley, Mewhinney & Strauss sold 523,113 Haemonetics shares in Q1 2026, an estimated $41.9M.
- Barrow, Hanley, Mewhinney & Strauss first reported a position in Haemonetics in Q4 2013 and held it in 16 quarters.
- Barrow, Hanley, Mewhinney & Strauss's Haemonetics position peaked at $105M in Q1 2015.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q1 2026, filed 13 May 2026.